A screening test for modified hemoglobin blood substitutes before clinical use: based on C3a complement activation in...

Area of Science:

• Biochemistry
• Immunology
• Pharmacology

Background:

• Modified hemoglobin preparations can cause adverse reactions, including hypersensitivity and anaphylaxis.
• Animal safety studies may not accurately predict human responses to these preparations.
• An in-vitro human plasma assay is needed to assess potential immunogenicity before clinical trials.

Purpose of the Study:

• To develop and validate an in-vitro screening procedure for detecting complement activation by modified hemoglobin preparations.
• To assess the potential of specific hemoglobin preparations (A and B) to induce complement C3a generation in human plasma.

Main Methods:

• Collected heparinized human plasma, stored at -70°C.
• Incubated plasma with test samples (hemoglobin preparations A, B, or mixtures) or controls (zymosan) at 37°C for 1 hour.
• Measured complement component C3a levels using radioimmunoassay after reaction termination and storage.

Main Results:

• Hemoglobin preparation A did not significantly increase C3a levels compared to controls.
• Hemoglobin preparation B caused a significant increase in C3a levels, indicating complement activation.
• The complement activation by Hemoglobin preparation B was dose-dependent and not due to C3 exhaustion.

Conclusions:

• The developed in-vitro assay effectively detects complement activation by modified hemoglobin preparations.
• Hemoglobin preparation B demonstrates immunogenic potential via complement activation, warranting caution.
• This assay serves as a valuable screening tool to identify potentially hypersensitive hemoglobin products before human trials.